Masalah Terkait Obat pada Pasien Onkologi: Apa yang Harus Diperhatikan oleh Apoteker?
Yovita Diane Titiesari(1), Helin Yovina Nursalim(2*), Jessica Nathania(3)
(1) Rumah Sakit Khusus Kanker MRCCC Siloam Semanggi
(2) Rumah Sakit Khusus Kanker MRCCC Siloam Semanggi
(3) Rumah Sakit Khusus Kanker MRCCC Siloam Semanggi
(*) Corresponding Author
Abstract
Keywords
Full Text:
PDFReferences
Boşnak, A. S., Birand, N., Diker, M., Abdi, A., & Başgut, B. (2018). The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy. Journal of Oncology Pharmacy Practice, 25(6), 1312– 1320. https://doi.org/10.1177/1078155218786048
Cehajic, I., Bergan, S., & Bjordal, K. (2015). Pharmacist assessment of drug-related problems on an oncology ward. European Journal of Hospital Pharmacy, 22(4), 194–197. https://doi.org/10.1136/ejhpharm-2014-000510
Fowler, H., Belot, A., Ellis, L., Maringe, C., Luque-Fernandez, M. A., Njagi, E. N., Navani, N., Sarfati, D., & Rachet, B. (2020). Comorbidity prevalence among cancer patients: a8 population-based cohort study of four cancers. BMC Cancer, 20(1). https://doi.org/10.1186/s12885-019-6472-9
Kementerian Kesehatan Republik Indonesia. (2016). Peraturan Menteri Kesehatan Republik Indonesia Nomor 72 Tahun 2016 Tentang Standar Pelayanan Kefarmasian Di Rumah Sakit. Departemen Kesehatan Republik Indonesia.
M Segal, E., Bates, J., Fleszar, S. L., Holle, L. M., Kennerly-Shah, J., Rockey, M., & Jeffers, K. D. (2019). Demonstrating the value of the oncology pharmacist within the healthcare team. Journal of Oncology Pharmacy Practice, 25(8), 1945–1967. https://doi.org/10.1177/1078155219859424
MIMS. (2020). MIMS Drug Reference Indonesia (144th ed.). MIMS Pte Ltd.
Pangribowo, S. (2019). Beban Kanker di Indonesia [E-book]. Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia. Pharmaceutical Care Network Europe Association (2020). PCNE Classification for Drug related problems V9.1. https://www.pcne.org/upload/files/417_PCNE_classification_V9- 1_final.pdf
Riechelmann, R. P., Tannock, I. F., Wang, L., Saad, E. D., Taback, N. A., & Krzyzanowska, M. K. (2007). Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients. JNCI Journal of the National Cancer Institute, 99(8), 592–600. https://doi.org/10.1093/jnci/djk130
Vacha, M. E., Huang, W., & Mando-Vandrick, J. (2015). The Role of Subcutaneous Ketorolac for Pain Management. Hospital Pharmacy, 50(2), 108–112. https://doi.org/10.1310/hpj5002-108
Weycker, D., Li, X., Edelsberg, J., Barron, R., Kartashov, A., Xu, H., & Lyman, G. H. (2015). Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors. Journal of Oncology Practice, 11(1), 47–54. https://doi.org/10.1200/jop.2014.001492
Zhang, P., Lv, D., Zhao, J., Sun, S., Li, L., & Liao, Y. (2021). Evaluation of pharmacists’ interventions on drug-related problems and drug costs in patients with cancer pain. International Journal of Clinical Pharmacy, 43(5), 1274–1282. https://doi.org/10.1007/s11096-021-01247-w
DOI: https://doi.org/10.22146/farmaseutik.v18i1.71911
Article Metrics
Abstract views : 6541 | views : 6880Refbacks
- There are currently no refbacks.